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Background: Indirect treatment comparison (ITC) and mixed treatment comparisons (MTC) have been increasingly
used in network meta-analyses. This simulation study comprehensively investigated statistical properties and
performances of commonly used ITC and MTC methods, including simple ITC (the Bucher method), frequentist and
Bayesian MTC methods.
Methods: A simple network of three sets of two-arm trials with a closed loop was simulated. Different simulation
scenarios were based on different number of trials, assumed treatment effects, extent of heterogeneity, bias and
inconsistency. The performance of the ITC and MTC methods was measured by the type I error, statistical power,
observed bias and mean squared error (MSE).
Results: When there are no biases in primary studies, all ITC and MTC methods investigated are on average
unbiased. Depending on the extent and direction of biases in different sets of studies, ITC and MTC methods may
be more or less biased than direct treatment comparisons (DTC). Of the methods investigated, the simple ITC
method has the largest mean squared error (MSE). The DTC is superior to the ITC in terms of statistical power and
MSE. Under the simulated circumstances in which there are no systematic biases and inconsistencies, the
performances of MTC methods are generally better than the performance of the corresponding DTC methods. For
inconsistency detection in network meta-analysis, the methods evaluated are on average unbiased. The statistical
power of commonly used methods for detecting inconsistency is very low.
Conclusions: The available methods for indirect and mixed treatment comparisons have different advantages and
limitations, depending on whether data analysed satisfies underlying assumptions. To choose the most valid
statistical methods for research synthesis, an appropriate assessment of primary studies included in evidence
network is required.
Keywords: Indirect comparison, Mixed treatment comparison, Network meta-analysis, Inconsistency, Bias, Type I
error, Statistical power, Simulation evaluationBackground
Indirect and mixed treatment comparisons have been
increasingly used in health technology assessment
reviews [1-4]. Indirect treatment comparison (ITC)
refers to a comparison of different treatments using
data from separate studies, in contrast to a direct treat-
ment comparison (DTC) within randomised controlled
trials. Statistical methods have been developed to* Correspondence: Fujian.Song@uea.ac.uk
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reproduction in any medium, provided the orindirectly compare multiple treatments and to combine
evidence from direct and indirect comparisons in mixed
treatment comparison (MTC) or network meta-analysis
[5-9].
The existing simple [5] or complex [6-8] statistical
methods for ITC and MTC are theoretically valid if cer-
tain assumptions can be fulfilled [2,10]. The relevant
assumptions could be specifically classified according to
a conceptual framework that delineates the homogeneity
assumption for conventional meta-analysis, the similarity
assumption for adjusted ITC, and the consistencytd. This is an Open Access article distributed under the terms of the Creative
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MTC [2,11]. Among the basic assumptions, heterogen-
eity in meta-analysis and inconsistency between direct
and indirect estimates can be quantitatively investi-
gated. The presence of inconsistency between direct
and indirect estimates has been empirically investigated
in meta-epidemiological studies and numerous cases
reports [12-16]. A range of statistical methods have
been suggested to investigate the inconsistency in net-
work meta-analysis [5,7,9,17-19].
The statistical properties of simple adjusted ITC [5]
have been previously evaluated in simulation studies
[1,20,21]. However, there are no simulation studies that
formally evaluate methods for Bayesian network meta-
analysis. In this simulation study, we comprehensively
evaluated properties and the performance of commonly
used ITC and MTC methods. Specifically, the objectives
of the study are (1) to investigate bias, Type I error and
statistical power of different comparison models for esti-
mating relative treatment effects, and (2) to investigate
bias, Type I error and statistical power of different com-
parison models for quantifying inconsistency between
direct and indirect estimates.
Methods
Comparison models investigated
We investigated the performance of the following ITC
and MTC statistical models.
Adjusted indirect treatment comparison (AITC)
This frequentist based method is also called as
Bucher’s method [5], based on the assumption that in-
direct evidence is consistent with the direct compari-
son. Suppose that treatment A and B are compared in
RCT-1 (with dAB as its result, logOR for example), and
treatment A and C compared in RCT-2 (with dACas its
result). Then treatment A can be used as a common
comparator to adjust the indirect comparison of treat-
ment B and C:
dIndBC ¼ dAB  dAC
Its variance is:
Var dIndBC
  ¼ Var dABð Þ þ Var dACð Þ
When there are multiple trials that compared treat-
ment A and B or treatment A and C, results from indi-
vidual trials can be combined using fixed-effect or
random-effects model. Then the pooled estimates of dAB
and dAC are used in the AITC.
Consistency frequentist MTC (CFMTC)
The results of frequentist ITC (using the Bucher’s
method) can be combined with the result of frequentistDTC in a MTC. The frequentist combination of the
DTC and ITC estimate is weighted by the corresponding
inverse of variance, as for pooling results from two indi-
vidual studies in meta-analysis [22].
This MTC is termed ‘consistency MTC’, as it assumes
that the result of direct comparison of treatment B and
C statistically equals to the result of indirect compari-
son of B and C based on the common comparator A
[9]. Suppose a network of three sets of trials that com-
pared A vs. B, A vs. C, and B vs. C, we only need to
estimate two basic parameters dAB and dAC, and the
third contrast (functional parameter) can be derived by
dBC = dAB - dAC.
Consistency Bayesian MTC (CBMTC)
As the CFMTC, this model is also based on the assump-
tion that ITC is consistent with DTC [8]. Suppose that
several treatments (A, B, C, and so on) are compared in
a network of trials. We need to select a treatment (treat-
ment A, for example, placebo or control) as the reference
treatment. In each study, we also consider a treatment
as the base treatment (b). Below is the general model for
the consistency MTC:
θkt ¼ μkb b ¼ A;B;C; if t ¼ bμkb þ δkbt t ¼ B;C;D; if t isafter b

δkbteN dbt ; τ2 
dbt ¼ dAt  dAb
dAA ¼ 0
Here θkt is the underlying outcome for treatment t in
study k, μkb is the outcome of treatment b, and δkbt is
the relative effect of treatment t as compared with treat-
ment b in study k. The trial specific relative effect δkbt is
assumed to have a normal distribution with a mean dbt
and variance τ2 (i.e., between study variance). When
τ2= 0, this model provides results as a fixed-effect
analysis.
Random Inconsistency Bayesian MTC (RIBMTC)
Some authors assumed that inconsistencies (that is,
the differences between dBC from direct compari-
sons and dIndBC based on indirect comparison) have a
common normal distribution with mean 0 and vari-
ance σ2ω [7,9]. These methods have been termed the
“random inconsistency model” [23]. In this study,
we evaluated the random inconsistency model by
Lu and Ades [9]. This model can be expressed by
the following:







Figure 1 Network of simulated trials.
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ωBCeN 0; σ2ω :
Here ωBC is termed inconsistency factor (ICF).
Inconsistency Bayesian Meta-Analysis (IBMA)
In the inconsistency Bayesian meta-analysis (IBMA),
each of the mean relative effects (dxy) is separately esti-
mated without using indirect treatment comparison in-
formation. The IBMA analysis is equivalent to a series of
pair-wise DTC meta-analyses, although a common
between-study variance (τ2) across different contrasts is
assumed [24].
We originally intended to include the Lumley’s fre-
quentist method for network meta-analysis [7]. However,
it was excluded because of convergence problems during
computer simulations.
Inconsistency test
Let dBC denote the natural log OR estimated by the
DTC, and dIndBC denote the log OR estimated by the ITC.
The inconsistency (ωBC) in the results between the direct
and indirect comparison of treatment B and C can be
calculated by the following:
ωBC ¼ dBC  dIndBC
When the estimated ωBC is greater than 0, it indicates
that the treatment effect is over-estimated by the ITC as
compared with the DTC. For Bucher’s method [5,12],
the calculation of inconsistency was based on the pooled
estimates of dBC and dIndBC by meta-analyses. The variance
of the estimated inconsistency was calculated by:
Var ωBCð Þ ¼ Var dBCð Þ þ Var dIndBC
 
where Var(dBC) and Var( dIndBC ) are the variance of dBC
and dIndBC respectively. The null hypothesis that the DTC





If the absolute value of ZBC is greater than 1.96, the
observed inconsistency is considered to be statistically
significantly different from zero.
The estimate of inconsistency is not applicable when
the consistency Bayesian MTC model [8] is used. With
the inconsistency Bayesian meta-analysis (IBMA), the es-
timate of dBC is naturally available, and dIndBC can be easily
estimated based on dAB and dAC, as by the “node-
splitting” method [17,24]. The point estimate of incon-
sistency in Bayesian MTC was the average (mean value)
of the simulated results. The significance of theinconsistency was based on the estimated 95% intervals.
If the 95% intervals did not contain the zero, the
observed inconsistency was considered to be statistically
significant.
The random inconsistency Bayesian MTC (RIBMTC)
model assumes that the inconsistency within a network
of trials is normally distributed with mean ω= 0 and
variance σ2ω [9]. We also recorded the estimated ω and
σ2ω by the RIBMTC model.
Simulation scenarios
In this study, a simple network of two-arm trials with a
closed loop was simulated to separately compare three
treatments: treatment 1 (T1, placebo), treatment 2 (T2,
an old drug), and treatment 3 (T3, a new drug) (Figure 1).
The comparison of T2 and T3 was considered as the
main interest. Trials that compared T1 vs. T2 and trials
that compared T1 vs. T3 were used for the indirect com-
parison of T2 and T3. Given the available resource, a
limited number of simulation scenarios were adopted in
this study. The following simulation parameters were
decided after considering characteristics of published
meta-analyses (also see Table 1).
 The number of patients in each arm of a pair-wise
trial is 100. The number of trials for each of the
three contrasts is 1, 5, 10, 20, 30 and 40. A scenario
of imbalanced number of trials (including a single
trial for one of the three sets) is also included.
 We use odds ratio (OR) to measure the outcome
[25]. The assumed true OR12 = 0.8, and the true
OR13 = 0.8 or 0.6. When OR is less than 1 (or log
OR< 0), it indicates that the risk of events is
reduced by the second of the two treatments
compared.
Table 1 Simulation input parameters
Parameters Values
Number of studies 3×40; 3×20; 3×10; 3×5; 3×1; 5/1/5
Number of patients per study 2×100
Between trial heterogeneity: τ2 0.00; 0.05; 0.10; 0.15
Treatment effect: log OR, θ12 log(0.8)
Treatment effect: log OR, θ13 log(0.8); log(0.6)
Bias: ROR12 0.00; 0.80
Bias: ROR13 0.00; 0.80
Bias: ROR23 0.00; 0.80
Baseline risk: P1 10%; 20%
(Note: these input values could be combined differently for a large number of
possible simulation scenarios).
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logOR23 ¼ logOR13  logOR12:
 The baseline risk in the control arm is assumed to
be 20% or 10%.
 It is assumed that heterogeneity is constant across
different comparisons, and there are four levels of
between study variance: τ2= 0.00, 0.05, 0.10, and
0.15 respectively [26].
 The trial-specific natural log OR (dkij) in study k
used to generate simulated trials is based on the
assumed true log OR and the between-trial variance:
dkijeN dij; τ2 :
 Given the baseline risk (Pk1) and the trial-specific
OR, the risk in the treatment arm in study k is
calculated by:

Pkt ¼ Pk1  Exp dk1tð Þ1 Pk1 þ Pk1  Exp dk1tð Þ :
 Bias in a clinical trial can be defined as a systematic
difference between the estimated effect size and
the true effect size [27]. It is assumed here that
all bias, where it exists, will result in an
over-estimated treatment effect of active drugs
(T2 and T3) as compared with placebo (T1),
and an over-estimated treatment effect of the
new drug (T3) relative to the old drug (T2). The
extent of bias and inconsistency is measured by
ratio of odds ratios (ROR). When ROR= 1,
it indicates that there is no bias. When ROR= 0.8,
it means that the effect (OR) of a treatment is
over-estimated by 20%.A network of trials was randomly generated, using
assumed input parameters (Table 1). For each arm of
the simulated trial, the number of events was randomly
generated according to the binomial distribution:
rkieBinomial Nki; Pkið Þ
Here, Nki is the number of patients in the arm of treat-
ment i, and Pki is the risk of events given treatment i in
study k. If the simulated number of events is zero, we
added 0.5 to the corresponding cells of the 2x2 table for
conducting inverse variance weighted meta-analysis.
Data analysis
AITC and MTC were conducted using data from the
simulated trials by fixed-effect and random-effects meta-
analyses. For frequentist ITC, we used inverse variance
weights to pool results of multiple trials in meta-analysis,
and used the DerSimonian-Laird method for random-
effects meta-analyses [22].
The performance of the ITC and MTC methods was
measured by the type I error rate or statistical power,
observed bias and mean squared error (MSE). We esti-
mated the rate of type I error (when the null hypothesis
is true) and the statistical power (when the null hypoth-
esis is false) by the proportion of significant estimates
(two sided α < 0.05) for the frequentist methods, or the
proportion of estimates with a 95% interval that did not
contain the zero treatment effect for the Bayesian
methods.
We generated 5000 simulated results for each of the
simulation scenarios in Table 1, and calculated the bias
and mean squared error (MSE) as:




ðθ_ c θ Þ




ðθ_ c θ Þ2
where ϑ is the true parameter value, _θ c is the estimated
value from the cth simulated data set. Monte Carlo 95%
intervals for estimated mean bias and inconsistency were
based on the 2.5% and 97.5% percentiles of the corre-
sponding estimates.
Computing implementation
Bayesian network meta-analyses were implemented by
Markov chain Monte Carlo (MCMC) methodology [8].
Vague or non-informative priors were used for MCMC
simulations. Each simulation comprised 20,000 ‘burn-in’
iterations followed by 40,000 posterior mean sample
iterations. Posterior mean samples collected were
thinned by a ratio of 5:1 to resulting in 8,000 final
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We used R 2.13.0 [28] and related packages (RJAGS) to
generate data and to sample Bayesian posterior distribu-
tions. All simulations were carried out on the High Per-
formance Computing Cluster supported by the Research
Computing Service at the University of East Anglia.Results
For the purpose of simplification, we only presented the
results of selected representative scenarios below.a: No. of studies=3x20






















c: No. of studies=3x5




Figure 2 Mean squared error (MSE) by different comparison models (
systematic bias in trials; fix, fixed effect; ran, random-effects; Tau2 refEstimating relative treatment effects
MSE and bias
As expected, mean squared error (MSE) is positively
associated with the small number of studies, and large
heterogeneity in meta-analysis (Figure 2). Of the com-
parison methods investigated, the AITC method has the
largest MSE. With the existence of heterogeneity, there
are no noticeable differences in MSE between the fixed-
effect and random-effects models.
When there is no bias in simulated trials, the results
of the all comparison methods are on average unbiasedb: No. of studies=3x10






















d: No. of studies=5/1/5




Note: baseline risk 20%; zero treatment effect; without
ers τ2).
a: All trials not biased 
-0.50 -0.25 0.00 0.25 0.50
Estimated bias (95% CI)
b: All trials are similarly biased  

























Estimated bias (95% CI)
c: Indirect comparison trials biased
-0.50 -0.25 0.00 0.25 0.50
Estimated bias (95% CI)
d: Direct comparison trials biased 
-0.50 -0.25 0.00 0.25 0.50
Estimated bias (95% CI)
Figure 3 Bias by different comparison methods (Note: selected simulation scenarios, baseline risk = 20%; τ2 = 0.05; number of studies
=3x20; random-effects analyses).
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and the inconsistency Bayesian MTC (RIBMTC) are fully
biased, while the AITC is not biased (Figure 3b). When
only the trials involved in AITC are biased, the DTC and
inconsistency MTC models are unbiased (Figure 3c).
The extent of bias in the consistency MTC models (both
CFMTC and CBMTC) lies between the DTC and ITC.
The impacts of biases in primary studies on the validity
of different comparison methods are summarised in
Table 2.Table 2 Impact of simulated biases on the results of different
Comparison methods
Trials not biased All t
Direct comparison (DTC) Not biased
Indirect comparison (AITC) Not biased
Consistency frequentist MTC Not biased M
Consistency Bayesian MTC Not biased M
Inconsistency Bayesian meta-analysis Not biased
Random inconsistency Bayesian MTC (RIBMTC) Not biased
(Note: “Fully biased” – the bias equals the bias in trials; “Moderately biased” – as a r
result of combining unbiased direct estimate and biased indirect estimate).Type I error
Assuming zero heterogeneity across studies, there are no
clear differences in the rate of type I error between dif-
ferent MTC methods (Figure 4). The extent of hetero-
geneity was clearly associated with inflated rates of type
I error. In the presence of great heterogeneity, the rate
of type I error is particularly large when fixed-effect
models are applied. The random-effects models tend to
have values closer to 0.05. However, random-effects
models no longer have advantages when there is only acomparison methods
Actual true biases
rials similarly biased One set of AIC trials biased DC trials biased
Fully biased Not biased Fully biased
Not biased Fully biased Not biased
oderately biased Moderately biased Moderately biased
oderately biased Moderately biased Moderately biased
Fully biased Not biased Fully biased
Fully biased Not biased Fully biased
esult of combining biased direct estimate and unbiased indirect estimate, or a
a: No. of studies =3x20




b: No. of studies=3x10




c: No. of studies=3x5 




d: No. of studies=3x1








































Figure 4 Type I error – proportion of significant results when true treatment effect is zero, impact of number of studies and assumed
heterogeneity (Note: baseline risk =20%; fix, fixed effect; ran, random-effects; Tau2 refers τ2).
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(Figure 4d). When there is only a single study for each
of the three contrasts, the rate of type I error is zero
by Bayesian random-effects models (CBMTC and
RIBMTC), which seems due to the unchanged vague
or non-informative priors [26]. Within the fixed-effect
models the different methods have similar type I error
rates, as well as within the random-effects models
(Figure 4).
As expected, the higher baseline risk (20%) is asso-
ciated with the higher rate of type I error as com-
pared with the lower baseline risk (10%) (data not
shown).Statistical power
As expected, the statistical power (1-β) is positively asso-
ciated with the number of studies (Figure 5). As com-
pared with the DTC, the statistical power of AITC is
low. The pooling of DTC and AITC evidence in MTC
increases the statistical power (Figure 5).
With a larger number of studies, the statistical power
of all methods is reduced by the presence of heterogen-
eity (Figure 5a-b). The association between heterogen-
eity and statistical power becomes unclear when the
number of studies is small (Figure 5c-d). When there is
only a single study, the statistical power of all the meth-
ods is extremely low, and it is zero by the Bayesian
a: No. of studies=3x20 




b: No. of studies=3x10




c: No. of studies=3x5




d: No. of studies=3x1 








































Figure 5 Statistical power to detect treatment effect (OR23= 0.75), impact of number of studies and assumed heterogeneity
(Note: Baseline risk =20%; fix, fixed effect; ran, random-effects; Tau2 refers τ2).
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informative priors) (Figure 5d).
A expected, the statistical power is reduced when the
baseline risk is lowered from 20% to 10% (data no
shown).
Inconsistency detecting
The estimated inconsistencies by the different compari-
son methods are on average unbiased, but the 95% inter-
vals are wide (Figure 6). The 95% interval of theestimated inconsistency by the RIBMTC method is
much wider than by other methods.
Heterogeneity is positively associated with the rate of
type I error for detecting inconsistency by the fixed-
effect models, while the number of studies does not no-
ticeably affect the rate of type I error (Figure 7). However,
when there is only a single study for each of the three
contrasts, the Bayesian random-effects method has zero
type I error (due to the vague or non-informative priors








0.0 1.0 2.0-2.0 -1.0
Figure 6 Estimated inconsistency (log ROR) – a selected
simulation scenario (Note: true logROR=0.223; baseline
risk = 20%; number of studies =3x20; τ2 = 0.10; Tau2 refers τ2).
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(Figure 7e). When there is imbalanced and singleton
number of trials, the frequentist random-effects model
has larger type I errors than the Bayesian random-effects
method (Figure 7f ).
The statistical power to detect the specified inconsist-
ency (P < 0.05) increases with the increasing number of
studies (Figure 8). However, the statistical power is still
lower than 70% even when there are 120 studies (200
patients in each study) in the trial network (Figure 8a).
By fixed-effect model, the existence of heterogeneity
generally increases the power to detect inconsistency.
However, the impact of heterogeneity on the power of
random-effects models is unclear. When there is only
one study for each of the three contrasts, the power by
Bayesian random-effects model is about zero (given
vague or non-informative priors for τ2) (Figure 8e).
Discussion
Summary of findings
Mean squared error (MSE) reflects a combination of
both bias and random error, which is clearly associated
with the number of studies, heterogeneity, and the base-
line risk. When simulated studies are not biased, the
AITC method had the largest MSE, as compared with
DTC and MTC methods. Given the same comparison
approach, there are no noticeable differences in esti-
mated MSE between the fixed-effect and random-effects
models.
When simulated trials are unbiased, the results of all
comparison methods investigated are good at predictingthe true magnitude and direction of the effect. However,
there are simulation scenarios under which AITC could
be biased. When all trials are similarly biased, the results
of AITC will be less biased than the results of DTC. This
finding is consistent with the result of a previous study
that evaluated the impacts of biases in trials involved in
AITC [29]. Bias by MTC will lie between the bias by
DTC and AITC (Table 2).
It should be noted that, in addition to the scenarios
simulated in this study, bias in original trials may also be
magnified if the two sets of trials for the AITC are
biased in opposite directions. For example, it is possible
that the relative effect of a treatment versus the common
comparator is over-estimated in one set of trials, and
under-estimated in another set of trials. Under this cir-
cumstance, the AITC estimate will be biased and the ex-
tent of such bias will be greater than the extent of bias
in the original studies.Estimating comparative treatment effect
The type I error of ITC and MTC methods are asso-
ciated with the extent of heterogeneity, whether a fixed-
effect or random-effects meta-analysis is used, and the
level of baseline risk. There are no noticeable differ-
ences in type I error between different comparison
methods.
As expected, the number of studies is clearly asso-
ciated with the statistical power to detect specified true
treatment effect. The AITC method has the lowest stat-
istical power. When there is no assumed inconsistency
or bias, the MTC increases the statistical power as
compared with the power of DTC alone. There are no
noticeable differences in the statistical power between
different MTC methods.Inconsistency testing
We found that the all comparison methods are on aver-
age unbiased for estimating the inconsistency between
the direct and indirect estimates. The 95% intervals by
the RIBMTC method are much wider than that by other
methods. Heterogeneity inflates the type I error in the
detection of inconsistencies by fixed-effect models.
When there are singleton studies in the trial network,
the frequentist based random-effects model has rela-
tively larger type I error than the Bayesian random-
effects model.
As expected, the power to detect inconsistency is posi-
tively associated with the number of studies and the use
of fixed-effect models. For the inconsistency detection,
heterogeneity increases the power of fixed-effect models,
but reduces the power of random-effects models when
the number of studies is large.
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c: No. of studies =3x10 





d: No. of studies =3x5 





e: No. of studies =3x1 





f: No. of studies =5/1/5 


























Figure 7 Type I error for inconsistency detection: impact of heterogeneity and number of studies (Note: baseline risk =20%, true
lnROR=0; tau2 refers τ2; Freq-fix, frequentist fixed-effect; Freq-ran, frequentist random-effects; Bay-fix, Bayesian fixed-effect; Bay-ran,
Bayesian random-effects).
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Methods of frequentist based indirect comparison have
been investigated in several previous simulation studies
[1,20,21]. A study found that the Bucher’s method and
logistic regression generally provided unbiased estimates
[1]. The simulation scenarios evaluated in that study was
limited by using data from a single trial. In another
study, Wells and colleagues simulated variance, bias and
MSE by the DTC and AITC method [21]. It was
reported that the observed variance, bias and MSE for
the AITC were larger than that for the DTC, particularly
when the baseline risk was low [21]. A more recent
simulation study by Mills and colleagues reported find-
ings from an investigation of the Bucher’s ITC method
[20]. They found that the AITC method lacks statisticalpower, particularly in the presence of heterogeneity, and
has high risk of over-estimation when only a single trial
is available in one of the two trial sets. However, they
did not compare the performance of the AITC and the
corresponding DTC or MTC [20].
Bayesian MTC methods have not been investigated in
previous simulation studies. In the current study, we
investigated the performance of statistical methods for
DTC, AITC, frequentist and Bayesian MTC. The simula-
tion results reveal the complex impacts of biases in pri-
mary studies on the results of direct, indirect and mixed
treatment comparisons. When the simulated primary
studies are not systematically biased, the AITC and
MTC methods are not systematically biased, although
the AITC method has the largest MSE. Depending on
a: No. of studies =3x40 









b: No. of studies =3x20 





c: No. of studies =3x10 





d: No. of studies =3x5 






e: No. of studies =3x1 





Note: Power ≈0 for Bay-ran
f: No. of studies =5/1/5 

























Figure 8 Statistical power to detect inconsistency: impact of heterogeneity and number of studies (Note: baseline risk =20%, true
lnROR=0.223; tau2 refers τ2. Freq-fix, frequentist fixed-effect; Freq-ran, frequentist random-effects; Bay-fix, Bayesian fixed-effect;
Bay-ran, Bayesian random-effects).
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AITC and MTC estimates could be more or less biased
than the DTC estimates.
In the existence of heterogeneity and a small number
of studies, AITC and MTC methods have indeed the
inflated rate of type I error and a low statistical power.
It is important to note that the performance of the corre-
sponding DTC is similarly affected. The performance
of the DTC method is superior to the performance of
the AITC method. However, the statistical power of
MTC is generally higher than the corresponding
DTC.
It is the first time that the power to detect incon-
sistency in network meta-analysis has been investi-
gated by simulations. The low power to detect
inconsistency in network meta-analysis seems similar
to the low power to detect heterogeneity in pair-wise
meta-analysis [30].Limitations of the study
Due to the restriction of available resource, a limited
number of simulation scenarios were considered.
Clearly, the performance of a model will depend on
whether the simulation scenario matches the model’s
assumptions. For example, the fixed-effect model should
not be used when there is heterogeneity across multiple
studies, in order to avoid the inflated type I error.
In this paper, the simple network containing three sets
of two-arm trials with a single completed loop is consid-
ered. We evaluated the methods for detecting inconsist-
ency, and did not consider models for investigating
causes of inconsistency. Therefore, further simulation
studies are required to evaluate complicated networks
involving more than three different treatments and con-
taining trials with multiple arms. In addition, further
simulation studies are required to evaluate the perform-
ance of regression models that incorporate study-level
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and inconsistency in network meta-analysis [18,19,31].
For MCMC simulations, we used vague or non-
informative priors [32]. When the number of studies
involved is large, finding of the study were unlikely to be
different if more informative priors had been used. How-
ever, further research is required to investigate whether
an informed prior for between-study variance would be
more appropriate when the number of studies involved
in a Bayesian meta-analysis is very small [26].
Implications to practice and research
The results of any comparison methods (including direct
comparison trials) may be biased as a consequence of
bias in primary trials involved. To decide which com-
parison method may provide more valid or less biased
results, it is helpful if we can estimate the extent and dir-
ection of possible biases in primary studies. Empirical
evidence indicated the existence of bias in randomised
controlled trials [33-35], particularly in trials that had
outcomes subjectively measured without appropriate
blinding [36,37]. Although it is usually difficult to esti-
mate the magnitude of bias, the likely direction of bias
may be estimated. For example, it may be assumed that
possible bias was likely to result in an over-estimation of
treatment effect of active or new drugs when they are
compared with placebo or old drugs [38]. More compli-
cated models could also be explored for estimating bias
in evidence synthesis [39-41].
For detecting inconsistency, the fixed-effect methods
have a higher rate of type I errors as well as a higher
statistical power as compared with the random-effects
methods. The performances of the Bayesian and fre-
quentist methods are generally similar. When there are
singleton trials in evidence network, the rate of type I
error by frequentist random-effects method is larger
than by the Bayesian random-effects method. This is
due to the under-estimation of between-study variance
by the frequentist method, while the Bayesian method
provides an estimate of between-study variance using all
data available in the whole network of trials [32]. How-
ever, when there is a single study for each of the all com-
parisons, Bayesian random-effects models should be
avoided.
Imbalanced distribution of effect-modifiers across
studies may be a common cause of both heterogeneity
in pair-wise meta-analysis and evidence inconsistency in
network meta-analysis [17]. However, it is helpful to dis-
tinguish the heterogeneity in pair-wise meta-analysis and
inconsistency in network meta-analysis. Under the as-
sumption of exchangeability, the results of direct and in-
direct comparisons could be consistent in the presence
of large heterogeneity in meta-analyses. For example, the
inflated type I error rate in detecting inconsistency bythe fixed-effect models can be corrected by the use of
random-effects models. It is also possible to observe sig-
nificant inconsistencies between direct and indirect esti-
mates when there is no significant heterogeneity in the
corresponding pair-wise meta-analyses. The association
between heterogeneity and the statistical power to detect
inconsistency is complex, depending on whether the
fixed-effect or random-effects model is used and the
number of studies involved.
A major concern is the very low power of commonly
used methods to detect inconsistency in network meta-
analysis when it does exist. Therefore, inconsistency in
network meta-analysis should not be ruled out based
only on the statistically non-significant result of a statis-
tical test. For all network meta-analysis, trial similarity
and evidence consistency should be carefully examined
[2,42].Conclusions
Of the comparison methods investigated, the indirect
comparison has the largest mean squared error and thus
the lowest certainty. The direct comparison is superior
to the indirect comparison in terms of statistical power
and mean squared error. Under the simulated circum-
stances in which there are no systematic biases and in-
consistencies, the performances of mixed treatment
comparisons are generally better than the performance
of the corresponding direct comparisons.
When there are no systematic biases in primary stud-
ies, all methods investigated are on average unbiased.
Depending on the extent and direction of biases in dif-
ferent sets of studies, indirect and mixed treatment com-
parisons may be more or less biased than the direct
comparisons. For inconsistency detection in network
meta-analysis, the methods evaluated are on average un-
biased. The statistical power of commonly used methods
for detecting inconsistency in network meta-analysis is
low.
In summary, the statistical methods investigated in this
study have different advantages and limitations, depend-
ing on whether data analysed satisfies the different
assumptions underlying these methods. To choose the
most valid statistical methods for network meta-analysis,
an appropriate assessment of primary studies included
in the evidence network is essential.Abbreviations
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